Solid tumors require blood vessels for growth, and many new cancer therapies are directed
against the tumor vasculature. The widely held view is that these antiangiogenic therapies …

The existence of factors that stimulate blood vessel growth, thereby recruiting a neovascular
supply to nourish a growing tumour, was postulated many decades ago, although the …

Resistance of human tumors to anticancer drugs is most often ascribed to gene mutations,
gene amplification, or epigenetic changes that influence the uptake, metabolism, or export of …

Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other
disorders, including age-related macular degeneration. Major progress towards a treatment …

Several vascular endothelial growth factor (VEGF)-targeted agents, administered either as
single agents or in combination with chemotherapy, have been shown to benefit patients …

Molecular imaging can allow the non-invasive assessment of biological and biochemical
processes in living subjects. Such technologies therefore have the potential to enhance our …

In addition to proliferating cancer cells and various types of normal cells, such as those of
the bone marrow, conventional cytotoxic chemotherapeutics affect the endothelium of the …

Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and
an angiogenic inducer in vivo. The tyrosine kinases Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR …

New blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and
metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway …

In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches
have yielded survival benefit in patients with metastatic cancer. In one approach, the …